<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02326961</url>
  </required_header>
  <id_info>
    <org_study_id>ACT-OA Knee</org_study_id>
    <nct_id>NCT02326961</nct_id>
  </id_info>
  <brief_title>Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee</brief_title>
  <acronym>ACT-OA Knee</acronym>
  <official_title>Celution Prepared Adipose Derived Regenerative Cells in the Treatment of Osteoarthritis of the Knee: A Double-blind, Placebo Controlled, Multi-center Safety and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cytori Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cytori Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the safety and feasibility of&#xD;
      intraarticular injection of Celution prepared adipose-derived regenerative cells injected&#xD;
      into knees of patients with chronic knee pain due to osteoarthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The ACT - OA Knee Clinical Trial is a prospective, randomized, multi-center device trial&#xD;
      intended to assess safety and feasibility of intraarticular administration of Celution&#xD;
      processed Adipose Derived Regenerative Cells (ADRCs). The study will include 90 patients in&#xD;
      up to 15 sites in the United States.&#xD;
&#xD;
      Subjects that have chronic knee pain due to idiopathic osteoarthritis of the knee (confirmed&#xD;
      clinically and radiologically) will be evaluated for eligibility in this study. Following&#xD;
      informed consent and screening evaluations, eligible subjects will undergo pre-operative&#xD;
      testing. Subjects will then undergo fat harvest through small volume liposuction under local&#xD;
      anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate&#xD;
      ADRCs for immediate intraarticular administration. A dose escalation approach has been&#xD;
      designed wherein the study is divided into two double-blind, randomized, placebo-controlled&#xD;
      parts as follows:&#xD;
&#xD;
      Part A:&#xD;
&#xD;
      Low Dose (20,000,000 cells): 30 patients OR Placebo: 15 patients&#xD;
&#xD;
      Part B:&#xD;
&#xD;
      High Dose (40,000,000 cells): 30 patients OR Placebo: 15 patients&#xD;
&#xD;
      Subjects randomized to placebo will undergo fat harvest and intraarticular injection of a&#xD;
      placebo that has been visually matched to the active test substance. All subjects will&#xD;
      undergo imaging studies, clinical evaluations, and laboratory testing prior to and after the&#xD;
      procedure; patients will be followed for 48 weeks after intraarticular injections are&#xD;
      performed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS) - Pain on Walking</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Observed Pain Scores on 50-foot Walk Test</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Observed OARS130 Responders</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Knee Injury and Osteoarthritis Outcome Score (KOOS)</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VAS Assessments</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Medication</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-36 Questionnaire</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI Osteoarthritis Knee Score</measure>
    <time_frame>48 Weeks</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events, Serious Adverse Events, and UADEs</measure>
    <time_frame>48 Weeks</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">94</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Celution ADRCs; Low Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 20,000,000 ADRCs per single intraarticular administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celution ADRCs; High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adipose Derived Regenerative Cells (ADRCs) processed by the Celution Device 40,000,000 ADRCs per single intraarticular administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sterile Lactated Ringers Solution (5mL) mixed with ≤ 0.20 ml of the study subject's own freshly drawn blood.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Celution Device</intervention_name>
    <description>ADRCs Prepared using the Celution Device</description>
    <arm_group_label>Celution ADRCs; High Dose</arm_group_label>
    <arm_group_label>Celution ADRCs; Low Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Inactive Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males or females ≥ 40 and &lt; 70 years of age&#xD;
&#xD;
          2. Able to provide written informed consent&#xD;
&#xD;
          3. Diagnosis of osteoarthritis in one or both knees by American College of Rheumatology&#xD;
             (ACR) criteria&#xD;
&#xD;
          4. Kellgren and Lawrence grade 2 or 3 (standing AP x-ray) of the target knee within the&#xD;
             preceding 6 months&#xD;
&#xD;
          5. Pain due to osteoarthritis in the target knee ≥ 6 months&#xD;
&#xD;
          6. Minimum score of &quot;moderate&quot; from KOOS question about pain on walking on a flat&#xD;
             surface.&#xD;
&#xD;
          7. Minimum score of &quot;moderate&quot; from KOOS question about degree of difficulty during&#xD;
             walking on a flat surface.&#xD;
&#xD;
          8. Continued knee pain and limitations in knee function despite prescription of&#xD;
             conservative therapy for at least 6 months.&#xD;
&#xD;
          9. Ability to safely undergo liposuction that will result in the harvest of a sufficient&#xD;
             quantity of adipose tissue (approximately 300 mL)&#xD;
&#xD;
         10. On stable regimen of one analgesic medication (rescue medication) for their knee pain&#xD;
             due to osteoarthritis and ability and willingness to use the same analgesic medication&#xD;
             during the study (screening period through to final study visit).&#xD;
&#xD;
         11. Ability to perform procedures required of the pain index evaluations (unassisted&#xD;
             walking 50 feet on a flat surface and going up and down stairs)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any major injury to the target knee within the 12 months prior to the screening visit&#xD;
&#xD;
          2. Need for cane or other assistance device for walking&#xD;
&#xD;
          3. Any surgery to the target knee within the 6 months prior to the screening visit, or&#xD;
             surgery to the contralateral knee or other weight-bearing joint if it will interfere&#xD;
             with knee assessments&#xD;
&#xD;
          4. Prior articular transplant procedures&#xD;
&#xD;
          5. Prior ligament reconstruction to the target knee within 12 months prior to the&#xD;
             screening visit&#xD;
&#xD;
          6. Inflammatory arthropathies such as rheumatoid arthritis, lupus arthropathy, or&#xD;
             psoriatic arthritis&#xD;
&#xD;
          7. Gout or calcium pyrophosphate (pseudogout) diseases that have flared within the&#xD;
             previous 6 months prior to the screening visit&#xD;
&#xD;
          8. X-ray findings of acute fractures, known severe loss of bone density (as determined by&#xD;
             the investigator), avascular necrosis, and/or severe bone or joint deformity in the&#xD;
             target knee (&gt;5 degree valgus or varus deviation from mechanical axis)&#xD;
&#xD;
          9. Fibromyalgia, pes anserine bursitis, lumbar radiculopathy, and/or neurogenic or&#xD;
             vascular claudication&#xD;
&#xD;
         10. Primary knee pain due to diagnosed isolated patella-femoral arthritis or&#xD;
             chondromalacia in the target knee&#xD;
&#xD;
         11. Significant target knee joint infection or skin disorder/infection within the previous&#xD;
             6 months prior to the screening visit&#xD;
&#xD;
         12. Symptomatic OA of the hips, spine, or ankle, if it would interfere with the evaluation&#xD;
             of the target knee&#xD;
&#xD;
         13. Any condition requiring immunosuppressive medication or use of systemic steroids&#xD;
&#xD;
         14. Intra-articular injection of steroids in previous 3 months or hyaluronic acid in&#xD;
             previous 6 months in one or both knees prior to the screening visit&#xD;
&#xD;
         15. Patients that have received PRP, other platelet-based product, or investigational&#xD;
             treatment in another cell/biologic study for the targeted treatment injury in the 12&#xD;
             months prior to the injection procedure&#xD;
&#xD;
         16. Participation in any experimental drug or device study within the 6 months prior to&#xD;
             the screening visit&#xD;
&#xD;
         17. Obesity defined as BMI &gt; 35 kg/m2&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Kesten, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cytori Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis and Rheumatology Research, PLLC</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Health Center for Clinical Research</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BioSolutions Clinical Research Center</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heartland Research Associates</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Kentucky Research Associates</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Covington Orthopedic and Sports Medicine Institute</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Treatment Center</name>
      <address>
        <city>Frederick</city>
        <state>Maryland</state>
        <zip>21702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Pharmaceutical Research</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>November 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 30, 2014</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee</keyword>
  <keyword>adipose derived regenerative cells</keyword>
  <keyword>ADRC</keyword>
  <keyword>Celution</keyword>
  <keyword>arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

